Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723021 · ClinicalTrials.gov registry record · Phase 2
PF-04191834 Single Dose Bronchodilatory Study In Asthma.
A Phase 2 study of Asthma, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 4
- Study locations
NCT00723021: Completed Phase 2 study of Asthma, sponsored by Pfizer.
NCT00723021 is a Phase 2 study of Asthma that has completed, run by Pfizer. The registered enrollment target is 15 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00723021, a Phase 2 study of Asthma, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 4
- Study locations
Study Summary
Study to determine the bronchodilatory effects of PF-04191834 compared with zileuton in patients with asthma
Primary Outcome
The FEV1 is the maximal volume of air that can be forcefully exhaled in one second
Conditions Studied
Interventions
- DRUG Placebo
- DRUG zileuton
- DRUG PF-04191834
Study Locations (4)
Maryland
- Pfizer Investigational Site - Baltimore
Massachusetts
- Pfizer Investigational Site - North Dartmouth
Michigan
- Pfizer Investigational Site - Kalamazoo
Nebraska
- Pfizer Investigational Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00723021 record still lists
NCT00723021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00723021 reports a single indexed study location in Maryland, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT00723021 about?
NCT00723021 is a clinical study titled "PF-04191834 Single Dose Bronchodilatory Study In Asthma.". Study to determine the bronchodilatory effects of PF-04191834 compared with zileuton in patients with asthma
What is the current status of trial NCT00723021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2008-07. Estimated completion is 2009-07.
What conditions does trial NCT00723021 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00723021?
The interventions under investigation include: Placebo (DRUG), zileuton (DRUG), PF-04191834 (DRUG).
Who is sponsoring clinical trial NCT00723021?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00723021 being conducted?
This trial has 4 study locations across Maryland, Massachusetts, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00723021's enrollment target sits among peer trials
15 354th of 374 higher than 17 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia